


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the Claims:**

1 (Previously presented). A pharmaceutical composition for dry powder inhalation in the respiratory tract of a [[mammal]] human, comprising a compound according to Formula (I) hereinbelow:



wherein

R2 and R3 are, independently, selected from the group consisting of straight or branched chain lower alkyl (having from 1 to 6 carbon atoms), cycloalkyl (having from 5 to 6 carbon atoms), 2-thienyl, 2-pyridyl, phenyl, phenyl substituted with an alkyl group having not in excess of 4 carbon atoms, and phenyl substituted with an alkoxy group having not in excess of 4 carbon atoms; and

X<sup>-</sup> represents an anion associated with the positive charge of the N atom; and a pharmaceutically acceptable carrier or diluent suitable for dry powder oral inhalation.

2 (previously presented). A pharmaceutical composition according to claim 1 wherein the orientation of the alkyl chain attached to the tropane ring is endo.

3 (previously presented). A pharmaceutical composition according to claim 2 wherein the compound of Formula (I) is selected from the group consisting of:  
(3-*endo*)-3-(2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide;  
and

(3-*endo*)-3-(2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane 4-methylbenzenesulfonate.

4 (previously presented). A pharmaceutical composition according to claim 1 wherein X<sup>-</sup> is selected from the group consisting of chloride, bromide, iodide, sulfate, benzene sulfonate and toluene sulfonate.

5. (Cancelled)

6. (currently amended) A method of inhibiting the binding of acetylcholine to [[a]] an acetylcholine receptor in a [[mammal]] human in need thereof, which comprises contacting the acetylcholine receptor with an effective amount of a composition according to claim 1, and wherein the method of contacting the receptor with the composition is via inhalation by the mouth of the [[mammal]] human.

7. (currently amended) A method of inhibiting the binding of acetylcholine to a M<sub>3</sub> muscarinic acetylcholine receptor in the respiratory tract of a [[mammal]] human in need thereof, which comprises contacting the M<sub>3</sub> muscarinic acetylcholine receptor with an effective amount of a composition according to claim 1 and wherein the method of contacting the receptor with the composition is via inhalation by the mouth of the [[mammal]] human.

8. (previously presented) A method according to claim 7 wherein the binding of the M<sub>3</sub> muscarinic acetylcholine receptor is useful in the treatment of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema or allergic rhinitis.

9. (previously presented) A method according to claim 7 wherein administration is via inhalation via the mouth from a medicament dispenser which is a reservoir dry powder inhaler.

10. (previously presented) A method according to claim 7 wherein administration is via inhalation via the mouth from a medicament dispenser which is a multi-dose dry powder inhaler.

11. (currently amended) A method according to claim 7 wherein the composition has a duration of action of 12 hours or more ~~and the mammal is a human.~~

12. (previously presented) A method according to claim 11 wherein the composition has a duration of action of 24 hours or more.

13. (previously presented) A method according to claim 12 wherein the composition has a duration of action of 36 hours or more.

14. (cancelled )

15. (previously presented) A method of treating chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema or allergic rhinitis in a human in need thereof, comprising administering to said human by inhalation via the mouth, an effective amount of a composition according to Claim 1.

16. (currently amended) The method according to Claim 15 wherein the treatment is for chronic obstructive lung disease or asthma.

17. (new) A method of administering to a human in need thereof, a pharmaceutical composition according to claim 1 wherein administration is via inhalation via the mouth.

18. (new) The method according to Claim 17 wherein the administration of the pharmaceutical composition is via inhalation via the mouth from a medicament dispenser which is a reservoir dry powder inhaler.

19. (new) The method according to Claim 17 wherein the administration of the pharmaceutical composition is via inhalation via the mouth from a medicament dispenser which is a multi-dose dry powder inhaler.

20. (new) The method according to Claim 17 wherein the administration of the pharmaceutical composition is via inhalation via the mouth from a medicament dispenser which is a metered dose inhaler.

21. (new) The composition according to Claim 1 wherein the pharmaceutically acceptable carrier or diluent suitable for dry powder oral inhalation is selected from lactose or starch.